Experimental CAR t therapy for myeloma shows early promise but trial halted
NCT ID NCT06304636
First seen Dec 08, 2025 · Last updated May 10, 2026 · Updated 18 times
Summary
This early-phase study tested a new treatment called Descartes-15 for people with multiple myeloma that had come back or stopped responding to other therapies. The treatment uses a patient's own immune cells, engineered with RNA to target cancer cells. Only 4 people were enrolled before the study was stopped, so results are very limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Center for Cancer and Blood Disorders (AON)
Bethesda, Maryland, 20817, United States
Conditions
Explore the condition pages connected to this study.